GLP-1 medications, which are used to treat diabetes and obesity, appear to be associated with reduced hospital care and sickness absence from work for psychiatric reasons, researchers reported… read more.
In terms of clinically relevant bleeding, apixaban is safer than rivaroxaban in the treatment of venous thrombosis, researchers concluded on March 11, 2026 in the NEJM/New England Journal of… read more.
Researchers at Arizona State University have uncovered a key scientific principle that governs how what’s coated on the surfaces of engineered nanoparticles may ultimately control how they work… read more.
Industrial yeasts are a powerhouse of protein production, used to manufacture vaccines, biopharmaceuticals, and other useful compounds. In a new study, MIT chemical engineers have harnessed artificial intelligence… read more.
As Washington debates how to rein in soaring prescription drug prices, including proposals that would tie U.S. prices to those paid abroad, a new study led by researchers… read more.
Cardiovascular disease results in around 20 million deaths worldwide and causes around a quarter of all deaths in the UK. Statins are highly effective drugs that lower LDL… read more.
The European Medicines Agency (EMA) has released a statement designed to clear up any remaining uncertainty about the use of paracetamol. In the EU, the drug watchdog says,… read more.
A new landmark study supports the safety of the common painkillers paracetamol and ibuprofen in the first year of life, and finds no link to eczema or bronchiolitis,… read more.
A new randomised controlled trial has found promising evidence that the smoking cessation medication varenicline (Chantix/Champix) can help people with cannabis use disorder (CUD) to reduce cannabis use. … read more.
Chemists at Ben-Gurion University of the Negev have developed a “smart” polymer that could make industrial curing, 3D printing and repairs simpler, safer and more energy-efficient with materials… read more.
Orexo AB announced the signing of an agreement with Dexcel Pharma to divest the full US rights to Zubsolv (buprenorphine/naloxone) sublingual tablet CIII, for the treatment of opioid… read more.
The study shows that this drug pair works far better together than either agent alone, offering a realistic and potentially fast path toward a new antifibrotic therapy. Liver… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
